Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates for the treatment of inflammatory bowel disease (IBD). The companies will also collaborate on detecting biomarkers related to clinical response for a maximum of five pipeline compounds of Gilead Sciences, […]
Polarisqb has joined forces with Fujitsu to create a Dengue drug discovery platform that brings together quantum-inspired technology, hybrid quantum mechanics, machine learning, and molecular mechanics simulations (QM/MM). The new platform is expected to help in significantly quicker, more cost-effective discovery of novel lead molecules for developing new drugs. Polarisqb and Fujitsu have started a […]
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in the therapeutic areas of oncology, immunology, fibrosis, and neurology. Peter Schultz – CEO of Scripps Research and Calibr, its drug discovery unit, said: “Based […]
GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing by advancing the field of 3D biofabrication. The companies said that the integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level evaluations […]
US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]
Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]
Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]
Israel-based Pepticom, which is engaged in using artificial intelligence (AI) for peptide drug discovery, has raised $5 million in a Series A funding round from the Chartered Group. Pepticom is a spin-out of Yissum, the technology transfer company of The Hebrew University of Jerusalem. The company’s artificial intelligence technology is said to optimize and significantly speed […]
Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round. The new capital will be used for investing in discovery research and pre-clinical development […]